Comparing the efficacy of urinary hCG vs recombinant hCG for final maturation of oocyte in gnrh antagonist IVF/ICSI cycle

Abstract

Aims and objectives: To compare the efficacy of urinary human chorionic gonadotropin (uhCG) vs recombinant human chorionic gonadotropin (rhCG) for triggering ovulation in gonadotropinreleasing hormone (GnRH) antagonist in vitro fertilization (IVF) cycle. Materials and methods: Two hundred patients who underwent GnRH antagonist IVF/ICSI cycles were analyzed, 100 of them received recombinant hCG 250 μg (injection overtrelle) and another group of 100 received urinary hCG (injection ovutrig) either 5000 IU or 10,000 IU for final oocyte maturation and ovulation trigger. The primary outcome measured was total oocytes retrieved and the secondary outcome measured 09 was the maturity rate fertilization rate, cleavage rate and clinical pregnancy rates were also compared. Results: Age, day 2 follicle stimulating hormone (FSH) and total dose of rFSH were comparable between the groups. There were no significant differences between the groups in terms of the mean number of oocytes retrieved per follicle (uhCG; 12.5, rhCG; 12.09, p-value-0.6698). Similarly, there was statistically no difference in any of the other parameters studied between the two groups. That is number of mature oocytes, number of fertilized oocytes and number of cleaved oocytes, as the p-value was not significant. The clinical pregnancy rate was somewhat higher in the uhCG group but was not statistically significant.Both treatments were well tolerated and there was no significant side effects for either drug. Conclusion: There is no difference in clinical outcomes between urinary and recombinant hCG for induction of final oocyte maturation. Additional factors, including the cost, drug availability and ease of administration, should be considered, when choosing gonadotropin type.